159 related articles for article (PubMed ID: 1639101)
21. Immunotherapy of multiple myeloma.
Huang YW; Vitetta ES
Stem Cells; 1995 Mar; 13(2):123-34. PubMed ID: 7540468
[TBL] [Abstract][Full Text] [Related]
22. Expression and production of interleukin 10 in human myeloma cell lines.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A
Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145
[TBL] [Abstract][Full Text] [Related]
23. Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model.
Matsuno H; Sawai T; Nezuka T; Uzuki M; Tsuji H; Nishimoto N; Yoshizaki K
Arthritis Rheum; 1998 Nov; 41(11):2014-21. PubMed ID: 9811057
[TBL] [Abstract][Full Text] [Related]
24. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
25. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors.
Sidell N; Taga T; Hirano T; Kishimoto T; Saxon A
J Immunol; 1991 Jun; 146(11):3809-14. PubMed ID: 2033252
[TBL] [Abstract][Full Text] [Related]
26. Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies.
Saito T; Yasukawa K; Suzuki H; Futatsugi K; Fukunaga T; Yokomizo C; Koishihara Y; Fukui H; Ohsugi Y; Yawata H
J Immunol; 1991 Jul; 147(1):168-73. PubMed ID: 2051018
[TBL] [Abstract][Full Text] [Related]
27. A ciliary neurotrophic factor-sensitive human myeloma cell line.
Gu ZJ; Zhang XG; Hallet MM; Lu ZY; Wijdenes J; Rossi JF; Klein B
Exp Hematol; 1996 Aug; 24(10):1195-200. PubMed ID: 8765494
[TBL] [Abstract][Full Text] [Related]
28. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
29. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models.
Libert C; Vink A; Coulie P; Brouckaert P; Everaerdt B; Van Snick J; Fiers W
Eur J Immunol; 1992 Oct; 22(10):2625-30. PubMed ID: 1327800
[TBL] [Abstract][Full Text] [Related]
30. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato K; Tsuchiya M; Saldanha J; Koishihara Y; Ohsugi Y; Kishimoto T; Bendig MM
Cancer Res; 1993 Feb; 53(4):851-6. PubMed ID: 8428365
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
[TBL] [Abstract][Full Text] [Related]
33. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
34. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
35. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
[TBL] [Abstract][Full Text] [Related]
36. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
37. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J
Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 6 and its receptor in the immune response and hematopoiesis.
Hirano T; Taga T; Matsuda T; Hibi M; Suematsu S; Tang B; Murakami M; Kishimoto T
Int J Cell Cloning; 1990 Jan; 8 Suppl 1():155-66; discussion 166-7. PubMed ID: 2324554
[TBL] [Abstract][Full Text] [Related]
39. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
40. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.
Schwabe M; Brini AT; Bosco MC; Rubboli F; Egawa M; Zhao J; Princler GL; Kung HF
J Clin Invest; 1994 Dec; 94(6):2317-25. PubMed ID: 7989587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
